Lyme Disease Vaccine in Final Clinical Trials

If you spend time hiking, gardening, or living near wooded areas, you know the constant anxiety of a tick bite. Fortunately, a new Lyme disease vaccine is in the final stages of clinical testing. This highly anticipated shot could soon offer a reliable and safe way to prevent this debilitating tick-borne illness.

Meet VLA15: The New Lyme Disease Vaccine

The pharmaceutical companies Pfizer and Valneva have partnered to develop a new Lyme disease vaccine candidate named VLA15. This vaccine is currently undergoing Phase 3 clinical trials, which is the final testing phase required before seeking approval from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

If the trial results are positive, Pfizer and Valneva plan to submit their regulatory applications by the end of 2026. This means the vaccine could be available to the public in time for the 2027 tick season. VLA15 is currently the only Lyme disease vaccine candidate in advanced clinical development, making it a critical project for global public health.

How the VLA15 Vaccine Works

VLA15 is a multivalent protein subunit vaccine. It targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria responsible for causing Lyme disease.

The mechanism of this vaccine is uniquely fascinating. Unlike most vaccines that fight off an infection after the bacteria enter your bloodstream, VLA15 acts inside the tick. When an infected tick bites a vaccinated person, it ingests the person’s blood, which is full of OspA antibodies. These antibodies enter the tick’s gut and neutralize the bacteria before it can move into the human host.

The vaccine is designed to protect against six specific serotypes of the Borrelia bacteria. These six strains represent the vast majority of Lyme disease cases found across North America and Europe.

To achieve full immunity, patients will likely need a primary series of three doses. The current trials are testing a schedule where participants receive doses at month zero, month two, and month six. Because antibody levels wane over time, a booster shot will likely be required right before the start of tick season to maintain peak protection.

Details of the Phase 3 Clinical Trial

The Phase 3 trial for VLA15 is known as the VALOR study, which stands for Vaccine Against Lyme for Outdoor Recreationists. The study aims to evaluate the safety, efficacy, and immune response of the vaccine.

The trial includes roughly 9,400 participants across the United States, Canada, and Europe. Researchers specifically selected trial sites in regions where Lyme disease is highly endemic. The study is highly inclusive regarding age, enrolling participants as young as five years old. This is an important detail because children who play outdoors are at a significantly high risk for tick bites.

The trial faced a brief hurdle in early 2023. Pfizer had to dismiss several thousand participants from sites operated by Care Access, a third-party clinical trial company. This decision was made after discovering violations of Good Clinical Practice guidelines at those specific locations. However, Pfizer successfully recruited additional participants at other clinics, and the clinical trial remains fully on track for its 2026 completion date.

Why the Previous Lyme Vaccine Disappeared

Older readers might remember that a Lyme disease vaccine used to exist. In 1998, the FDA approved a vaccine called LYMErix, developed by GlaxoSmithKline. However, the manufacturer voluntarily pulled it from the market in 2002.

LYMErix failed for a variety of reasons, none of which had to do with actual safety hazards. Sales were remarkably low, largely because the vaccine required three doses over an entire year before reaching peak efficacy of 78 percent. Furthermore, a wave of negative media coverage generated public fear. Some people claimed the vaccine caused autoimmune arthritis.

The FDA and the Centers for Disease Control and Prevention (CDC) heavily investigated these claims. Both agencies concluded there was no scientific evidence linking LYMErix to arthritis. Regardless, the public backlash led to plunging sales, and GlaxoSmithKline halted production.

To prevent a repeat of this history, Pfizer and Valneva engineered VLA15 to be even safer. They removed a specific protein sequence from the vaccine that caused the public concern regarding arthritis in the 1990s. This adjustment virtually eliminates the theoretical risk of autoimmune reactions.

The Urgent Need for a Vaccine

The demand for a Lyme disease vaccine is higher today than it was twenty years ago. The CDC estimates that approximately 476,000 Americans are treated for Lyme disease every year.

Untreated Lyme disease can cause serious health complications. While early symptoms include fever, fatigue, and the classic erythema migrans (bullseye) rash, the infection can spread deeply into the body. Late-stage Lyme disease can lead to severe joint pain, facial palsy, heart palpitations, and memory issues. Climate change and expanding deer populations are allowing the black-legged tick (deer tick) to thrive in new geographic areas, making a vaccine a medical necessity.

What to Do While Waiting for Approval

Since VLA15 will not be available until at least 2026, you must rely on traditional preventative measures.

When walking in wooded or brushy areas, treat your clothing and boots with Permethrin (a 0.5 percent solution). For exposed skin, apply EPA-registered insect repellents containing DEET, Picaridin, or Oil of Lemon Eucalyptus. Always perform a thorough full-body tick check after spending time outdoors, and tumble dry your hiking clothes on high heat for ten minutes to kill any hidden ticks.

Frequently Asked Questions

When will the new Lyme disease vaccine be available? If the ongoing Phase 3 clinical trials are successful, Pfizer and Valneva plan to submit their data to the FDA in late 2026. The vaccine could be available to the public in 2027.

Is the new Lyme disease vaccine safe? Yes. Phase 1 and Phase 2 trials showed that VLA15 is safe and well-tolerated. The current Phase 3 trial involves thousands of participants to further confirm its safety profile.

Can children get the new Lyme disease vaccine? Yes. The current VALOR clinical trial includes children as young as five years old. Pediatric safety is a major focus since children are highly susceptible to tick bites.

Will this vaccine protect against other tick-borne diseases? No. The VLA15 vaccine targets the specific bacteria that causes Lyme disease. It will not protect against other tick-borne illnesses like Anaplasmosis, Babesiosis, or Rocky Mountain Spotted Fever. You must still practice tick prevention even after vaccination.